Blood Propofol Concentrations in Children During Spinal Surgery
Comparison of Measured Versus Predicted Blood Propofol Concentrations During Total Intravenous Anaesthesia in Children Undergoing Spinal Surgery
During major spinal surgery evoked potential monitoring is performed to detect spinal cord damage. Intra-venous anaesthesia is the preferred anaesthetic technique because volatile anaesthetic agents supress the evoked potentials. Total Intra-Venous Anaesthesia (TIVA) with propofol is commonly administered as a Target Controlled Infusion (TCI). The TCI is an automated drug delivery system which administers propofol to achieve a desired blood concentration, based on an in built pharmaco-kinetic data (TCI model) derived from previous studies. The TCI model also provides a real time predicted blood concentration to facilitate the anaesthetist to adjust the target concentration of propofol.
The TCI algorithm is based on pharmaco-kinetic data derived from previous studies in a relatively small number of patients, by a "best fit" relationship between blood levels, infusion rates and other factors (such as age and weight). Several factors make it possible for a wide discrepancy between the predicted and the true blood concentrations. This difference can be higher in children compared to adults. Also blood loss and administration of large volumes of intravenous fluids can affect the blood concentrations. This study aims to identify the difference between the predicted and true blood concentrations by using Pelorus 1500, a bedside blood propofol measurement device, in children undergoing major spinal surgery under TIVA.
Přehled studie
Postavení
Intervence / Léčba
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 4
Kontakty a umístění
Studijní místa
-
-
-
London, Spojené království, WC1N 3JH
- Great Ormond Street Hospital for Children NHS Trust
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Children undergoing major spinal surgery under propofol TCI
- Surgery expecting to last more than 3 hours.
Exclusion Criteria:
- Major hepatic or renal disease
Studijní plán
Jak je studie koncipována?
Detaily designu
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Single arm
The intervention in this study involves taking blood sample from an existing arterial line for measurement of blood propofol levels.
The drug in evaluation is Propofol 2% (Diprivan 2%, Astra Zeneca UK) administered as a target controlled infusion using the commercially available paediatric TCI models (Paedfusor and Marsh models).
The dose range is usually between a target concentration of 3-8 mcg/ml.
However the anaesthetic management is not changed for the study.
The blood concentrations of propofol will be measured using Pelorus 1500 (Sphere Medical, UK), a CE marked device.
The anaesthetist will be blinded from the measurements, unless the measured value was outside the safe limit ( < 3 mcg/ml or > 10mcg/ml).
|
a bedside blood propofol measurement device
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
The absolute difference between the measured and predicted concentrations of propofol in micrograms per ml of blood.
Časové okno: Up to 5 hours during the maintenance phase of anaesthesia, to allow a maximum of 10 samples at 20 to 30 min intervals.
|
Up to 5 hours during the maintenance phase of anaesthesia, to allow a maximum of 10 samples at 20 to 30 min intervals.
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Median Performance Error (MDPE)
Časové okno: Up to 5 hours during the maintenance phase of anaesthesia, to allow a maximum of 10 samples at 20 to 30 min intervals.
|
The median value of ratio between the measured and predicted concentration of propofol to the predicted concentration (Performance error) in blood.
Expressed as a percentage.
This is a measure of overall bias of the target controlled infusion.
|
Up to 5 hours during the maintenance phase of anaesthesia, to allow a maximum of 10 samples at 20 to 30 min intervals.
|
|
Median Absolute Performance Error (MDAPE)
Časové okno: Up to 5 hours during the maintenance phase of anaesthesia
|
The median value of the ratio of the absolute difference (excluding the sign) between the measured and predicted concentrations to the predicted concentration (Absolute performance error) in blood.
Expressed as percentage.
This is a measure of the accuracy of the target controlled infusion.
|
Up to 5 hours during the maintenance phase of anaesthesia
|
|
Wobble
Časové okno: Up to 5 hours during the maintenance phase of anaesthesia
|
The median value of the difference between the individual performance errors and the Median Performance Error (MDPE).
This is a measure of the distribution of the performance errors around the median.
|
Up to 5 hours during the maintenance phase of anaesthesia
|
|
Divergence
Časové okno: Up to 5 hours during the maintenance phase of anaesthesia
|
The median of the regression coefficient of the performance error against time.
This is a measure of how the target controlled infusion performs with time.
|
Up to 5 hours during the maintenance phase of anaesthesia
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Ředitel studie: Michael RJ Sury, FRCA PhD, Great Ormond Street Hospital for Children NHS Foundation Trust
- Vrchní vyšetřovatel: Selvakumar Panchatsharam, MBBS FRCA, Great Ormond Street Hospital for Children NHS Foundation Trust
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 12AR04
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .